Multi-epitope HER2 Peptide Vaccine TPIV100
MC1835-ACCRU-BR-1701
Phase 2 mab active
Quick answer
Multi-epitope HER2 Peptide Vaccine TPIV100 for Breast Adenocarcinoma is a Phase 2 program (mab) at UNITED THERAPEUTICS Corp with 1 ClinicalTrials.gov record(s).
Program details
- Company
- UNITED THERAPEUTICS Corp
- Indication
- Breast Adenocarcinoma
- Phase
- Phase 2
- Modality
- mab
- Status
- active